Cellectis (NASDAQ:CLLS) Rating Increased to Buy at StockNews.com

Cellectis (NASDAQ:CLLS - Get Free Report) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating in a report released on Friday.

Cellectis Price Performance

Shares of CLLS traded up $0.02 on Friday, hitting $1.53. The company's stock had a trading volume of 81,346 shares, compared to its average volume of 145,386. The company has a 50 day moving average price of $1.33 and a 200 day moving average price of $1.62. Cellectis has a fifty-two week low of $1.10 and a fifty-two week high of $3.38. The company has a market capitalization of $85.04 million, a PE ratio of -1.18 and a beta of 3.22. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.78 and a quick ratio of 1.78.

Cellectis (NASDAQ:CLLS - Get Free Report) last announced its earnings results on Thursday, March 13th. The biotechnology company reported ($0.16) EPS for the quarter, missing the consensus estimate of $0.06 by ($0.22). Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The business had revenue of $33.22 million for the quarter, compared to the consensus estimate of $5.90 million. On average, research analysts anticipate that Cellectis will post -0.46 earnings per share for the current fiscal year.

Institutional Trading of Cellectis

Several hedge funds have recently modified their holdings of CLLS. B Group Inc. acquired a new position in Cellectis during the 4th quarter worth $5,547,000. Millennium Management LLC bought a new stake in shares of Cellectis during the fourth quarter worth $962,000. Finally, Wells Fargo & Company MN raised its position in shares of Cellectis by 103.4% during the fourth quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company's stock worth $44,000 after acquiring an additional 12,500 shares during the last quarter. 63.90% of the stock is owned by institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.